ROIVW (Roivant Sciences) Pretax Margin %: 18,019.72% (As of Mar. 2026)


ROIVW Roivant Sciences Ltd ROIVW
55 GF Score
Price $2.75
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Pretax Margin %?

Roivant Sciences ROIVW -3.85% 55 Pretax Margin % is 18,019.72% as of Mar. 2026. GuruFocus rates ROIVW with a GF Score™ of 55/100. The stock has 7 warning signs investors should review. Among 946 Biotechnology companies, Roivant Sciences ranks worse than 87% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Roivant Sciences's Pre-Tax Income for the three months ended in Mar. 2026 was $454.10 Mil. Roivant Sciences's Revenue for the three months ended in Mar. 2026 was $2.52 Mil. Therefore, Roivant Sciences's pretax margin for the quarter that ended in Mar. 2026 was 18,019.72%.

The historical rank and industry rank for Roivant Sciences's Pretax Margin % or its related term are showing as below:

ROIVW' s Pretax Margin % Range Over the Past 10 Years
Min: -3776.2   Med: -2576.42   Max: 13963.43
Current: -3203.12

ROIVW's Pretax Margin % is ranked worse than
87% of 946 companies
in the Biotechnology industry
Industry Median: -90.5 vs ROIVW: -3203.12

Roivant Sciences  (NAS:ROIVW) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Roivant Sciences Pretax Margin % Related Terms

Roivant Sciences Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Pretax Margin % Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Pretax Margin %
Get a 7-Day Free Trial -1,670.85 -2,806.82 13,963.43 -2,346.02 -3,203.12

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,682.35 -12,408.39 -10,123.74 -14,525.71 18,019.72

ROIVW vs INSM, INCY, BNTX: Pretax Margin % Comparison

For the Biotechnology subindustry, Roivant Sciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Pretax Margin % falls into.


ROIVW
55GF Score
Roivant Sciences Ltd ROIVW
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Roivant Sciences's Pretax Margin for the fiscal year that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-264.578/8.26
=-3,203.12 %

Roivant Sciences's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=454.097/2.52
=18,019.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 18,019.72% mean?
Roivant Sciences (ROIVW) has a Pretax Margin % of 18,019.72% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #823 out of 946 companies in the Biotechnology industry, placing it in the top 87%.
Is Roivant Sciences' Pretax Margin % too high?
Roivant Sciences' current Pretax Margin % is 18,019.72%. Based on the distribution chart, Roivant Sciences ranks #823 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Pretax Margin % compare to INSM and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #823 out of 946 companies for Pretax Margin %. This places Roivant Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Pretax Margin % is 18,019.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Roivant Sciences (ROIVW) has a current Pretax Margin % of 18,019.72%. The current Pretax Margin % is 18,019.72%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Roivant Sciences (ROIVW), the current Pretax Margin % is 18,019.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIVW

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price